Pharmacotherapy for attention-deficit/hyperactivity disorder

被引:1
作者
Kim, Bongseog [1 ]
机构
[1] Inje Univ, Sanggye Paik Hosp, Coll Med, Dept Psychiat, Seoul, South Korea
来源
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | 2019年 / 62卷 / 01期
关键词
Attention deficit disorder with hyperactivity; Pharmacotherapy; Methylphenidate; Atomoxetine hydrochloride; DEFICIT-HYPERACTIVITY DISORDER; PROSPECTIVE FOLLOW-UP; EXTENDED-RELEASE; CHILDREN; ADHD; ADOLESCENTS; ATOMOXETINE; PREDICTORS; MEDICATION; OUTCOMES;
D O I
10.5124/jkma.2019.62.1.49
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder defined by impairing levels of inattention, disorganization, and/or hyperactivity-impulsivity. ADHD often persists into adulthood, with resultant impairments of social, academic and occupational functioning. ADHD is a very common disease during childhood and, the pooled overall prevalence of ADHD was found to be 5.29%. When screening for ADHD, clinicians should try to develop rapport with patients and their caregivers to increase the likelihood that they will follow the diagnostic process and treatment. The current drugs that have received Food and Drug Administration-approval for ADHD include stimulants (methylphenidate and dextroamphetamine) and non-stimulants (atomoxetine, guanfacine, and clonidine). Stimulants improve inattention, hyperactivity, and impulsivity in addition to decreasing disruptive behaviors and promoting academic achievement and the maintenance of appropriate friendships. In order to enhance drug compliance, the use of long-acting stimulants is increasing. Atomoxetine is a selective norepinephrine reuptake blocker, the effects of which may take 2 to 6 weeks to be noticeable. Furthermore, alpha 2 agonists may help to improve behavioral side effects, tics, and sleep problems during stimulant or atomoxetine use. Common side effects of stimulants and atomoxetine include headache, stomachache, and loss of appetite. Routine electorcardiography before medication is not recommended unless there is a specific indication. Methylphenidate and atomoxetine are safe as first line therapies, and their side effects are well tolerated.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 40 条
[1]  
[Anonymous], ADHD PAR MED GUID
[2]  
[Anonymous], 2013, DIAGNOSTIC STAT MANU, VFifth, P1000, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
[3]   Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: Results from a population-based study [J].
Barbaresi, WJ ;
Katusic, SK ;
Colligan, RC ;
Weaver, AL ;
Leibson, CL ;
Jacobsen, SJ .
JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2006, 27 (01) :1-10
[4]   THE ADOLESCENT OUTCOME OF HYPERACTIVE-CHILDREN DIAGNOSED BY RESEARCH CRITERIA .1. AN 8-YEAR PROSPECTIVE FOLLOW-UP-STUDY [J].
BARKLEY, RA ;
FISCHER, M ;
EDELBROCK, CS ;
SMALLISH, L .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1990, 29 (04) :546-557
[5]   The behavior of children receiving benzedrine [J].
Bradley, C .
AMERICAN JOURNAL OF PSYCHIATRY, 1937, 94 :577-585
[6]  
Briars Leslie, 2016, J Pediatr Pharmacol Ther, V21, P192, DOI 10.5863/1551-6776-21.3.192
[7]   Adolescent Outcomes of Childhood Attention-Deficit/Hyperactivity Disorder in a Diverse Community Sample [J].
Bussing, Regina ;
Mason, Dana M. ;
Bell, Lindsay ;
Porter, Phillip ;
Garvan, Cynthia .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2010, 49 (06) :595-605
[8]   Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis [J].
Cheng, Jackie Y. W. ;
Chen, Ronald Y. L. ;
Ko, John S. N. ;
Ng, Emil M. L. .
PSYCHOPHARMACOLOGY, 2007, 194 (02) :197-209
[9]   ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults [J].
Cooper, William O. ;
Habel, Laurel A. ;
Sox, Colin M. ;
Chan, K. Arnold ;
Arbogast, Patrick G. ;
Cheetham, T. Craig ;
Murray, Katherine T. ;
Quinn, Virginia P. ;
Stein, C. Michael ;
Callahan, S. Todd ;
Fireman, Bruce H. ;
Fish, Frank A. ;
Kirshner, Howard S. ;
O'Duffy, Anne ;
Connell, Frederick A. ;
Ray, Wayne A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (20) :1896-1904
[10]   Clonidine Extended-Release In Attention-Deficit Hyperactivity Disorder Profile Report [J].
Croxtall, Jamie D. .
CNS DRUGS, 2012, 26 (03) :277-279